NeuroNova and Genentech in VEGF licensing deal
This article was originally published in Scrip
Executive Summary
NeuroNova and Genentech have struck a licence and option agreement for developing VEGF as a potential treatment for amyotrophic lateral sclerosis, also known as Lou Gehrig's disease.